165 related articles for article (PubMed ID: 36823017)
21. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
22. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
23. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P
ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835
[TBL] [Abstract][Full Text] [Related]
25. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
[TBL] [Abstract][Full Text] [Related]
26. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
[TBL] [Abstract][Full Text] [Related]
28. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
30. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
Mori K; Yanagisawa T; Fukuokaya W; Iwatani K; Matsukawa A; Katayama S; Pradere B; Laukhtina E; Rajwa P; Moschini M; Albisinni S; Krajewski W; Cimadamore A; Del Giudice F; Teoh J; Urabe F; Kimura S; Murakami M; Tsuzuki S; Miki J; Miki K; Shariat SF; Kimura T;
Int J Urol; 2024 Jan; 31(1):25-31. PubMed ID: 37840031
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
33. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out.
Esteban-Villarrubia J; Romero Ferreiro C; Carril-Ajuria L; Carretero-González A; Iacovelli R; Albiges L; Castellano D; de Velasco G
Urol Oncol; 2023 Sep; 41(9):391.e13-391.e21. PubMed ID: 37331822
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
37. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
38. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
39. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
40. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
